JP2006514607A - 長時間持続性ナトリウム排泄増加性ペプチド誘導体 - Google Patents

長時間持続性ナトリウム排泄増加性ペプチド誘導体 Download PDF

Info

Publication number
JP2006514607A
JP2006514607A JP2004523679A JP2004523679A JP2006514607A JP 2006514607 A JP2006514607 A JP 2006514607A JP 2004523679 A JP2004523679 A JP 2004523679A JP 2004523679 A JP2004523679 A JP 2004523679A JP 2006514607 A JP2006514607 A JP 2006514607A
Authority
JP
Japan
Prior art keywords
absent
ala
arg
seq
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004523679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514607A5 (enExample
Inventor
ドミニク ピー． ブリドン，
ピーター バキス，
ジュリー カレッテ，
フランス レクレア，
ロジャー レガー，
マーティン ロビタイル，
Original Assignee
コンジュケム，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンジュケム，インコーポレーテッド filed Critical コンジュケム，インコーポレーテッド
Publication of JP2006514607A publication Critical patent/JP2006514607A/ja
Publication of JP2006514607A5 publication Critical patent/JP2006514607A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
JP2004523679A 2002-07-31 2003-07-29 長時間持続性ナトリウム排泄増加性ペプチド誘導体 Pending JP2006514607A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40041302P 2002-07-31 2002-07-31
US40019902P 2002-07-31 2002-07-31
PCT/CA2003/001097 WO2004011498A2 (en) 2002-07-31 2003-07-29 Long lasting natriuretic peptide derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009273992A Division JP2010047614A (ja) 2002-07-31 2009-12-01 長時間持続性ナトリウム排泄増加性ペプチド誘導体

Publications (2)

Publication Number Publication Date
JP2006514607A true JP2006514607A (ja) 2006-05-11
JP2006514607A5 JP2006514607A5 (enExample) 2006-09-07

Family

ID=31191354

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004523679A Pending JP2006514607A (ja) 2002-07-31 2003-07-29 長時間持続性ナトリウム排泄増加性ペプチド誘導体
JP2009273992A Pending JP2010047614A (ja) 2002-07-31 2009-12-01 長時間持続性ナトリウム排泄増加性ペプチド誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009273992A Pending JP2010047614A (ja) 2002-07-31 2009-12-01 長時間持続性ナトリウム排泄増加性ペプチド誘導体

Country Status (5)

Country Link
EP (1) EP1530588A2 (enExample)
JP (2) JP2006514607A (enExample)
AU (1) AU2003246500A1 (enExample)
CA (1) CA2488348A1 (enExample)
WO (1) WO2004011498A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008162987A (ja) * 2006-12-31 2008-07-17 Toshiko Koide 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法
JP2014506584A (ja) * 2011-02-23 2014-03-17 マデライン ファーマシューティカルズ ピーティーワイ リミテッド うっ血性心不全を処置するための治療方法
JP2021073234A (ja) * 2015-05-29 2021-05-13 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
SG159387A1 (en) 2002-11-26 2010-03-30 Biocon Ltd In Modified natriuretic compounds, conjugates, and uses thereof
EP1727556A2 (en) 2004-02-17 2006-12-06 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
WO2006005140A2 (en) 2004-07-15 2006-01-19 The University Of Queensland Proteinaceous compounds and uses therefor
WO2006094764A1 (en) * 2005-03-07 2006-09-14 Mondobiotech Licensing Out Ag Formulation for aviptadil
WO2006108686A2 (en) * 2005-04-14 2006-10-19 Aic Bnp agonists
WO2007041645A2 (en) * 2005-10-03 2007-04-12 Scios Inc. Oxidized human bnp
EP2051585A4 (en) 2006-04-28 2010-06-02 Univ South Florida MATERIALS AND METHODS OF SUPPRESSING INFLAMMATION THROUGH INHIBITION OF THE VORHOF RECEPTOR FOR NATRIURETIC PEPTIDES
KR20080098216A (ko) * 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
US20100310561A1 (en) * 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
AU2008274845A1 (en) 2007-07-06 2009-01-15 Theratechnologies Inc. Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-MSH) and atrial natriuretic protein (ANP) and uses in hypertension and acute kidney injury
WO2012013597A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
DE102010032482A1 (de) 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe zur Beeinflussung der natriuretischen Peptid-Rezeptoren A und B und deren Verwendung
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
CN102286092B (zh) 2011-09-14 2014-01-01 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN120435308A (zh) 2022-10-21 2025-08-05 伊莱利利公司 长效利尿钠肽及其用途
CN116284329B (zh) * 2023-04-28 2023-12-08 成都奥达生物科技有限公司 一种长效利钠肽化合物
CN121717878A (zh) * 2024-12-02 2026-03-24 中山大学 一种用于npr-b靶向的超长效多肽及其在骨骼系统病症中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501294A (ja) * 1985-11-05 1988-05-19 カリフォルニア・バイオテクノロジー・インク 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JPH04500363A (ja) * 1989-05-24 1992-01-23 アボツト・ラボラトリーズ 心房ペプチド誘導体
JP2000191688A (ja) * 1985-11-05 2000-07-11 Scios Inc 心房性ナトリウム尿排泄亢進ペプチド類似化合物
WO2000070665A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001017614A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63501294A (ja) * 1985-11-05 1988-05-19 カリフォルニア・バイオテクノロジー・インク 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JP2000191688A (ja) * 1985-11-05 2000-07-11 Scios Inc 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JP2002167396A (ja) * 1985-11-05 2002-06-11 Scios Inc 心房性ナトリウム尿排泄亢進ペプチド類似化合物
JPH04500363A (ja) * 1989-05-24 1992-01-23 アボツト・ラボラトリーズ 心房ペプチド誘導体
WO2000070665A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001017614A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
WO2001017568A2 (en) * 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008162987A (ja) * 2006-12-31 2008-07-17 Toshiko Koide 心房利尿ホルモンファミリー分子を活性物質として含有する組織再生製剤また該製剤をもちいる組織再生方法、および心房利尿ホルモンファミリー分子を活性物質として含有する発毛、増毛、育毛剤および皮膚組織修復改善剤また該製剤を用いる発毛、増毛、育毛促進方法および皮膚組織修復改善方法
JP2014506584A (ja) * 2011-02-23 2014-03-17 マデライン ファーマシューティカルズ ピーティーワイ リミテッド うっ血性心不全を処置するための治療方法
JP2021073234A (ja) * 2015-05-29 2021-05-13 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料
JP2023096139A (ja) * 2015-05-29 2023-07-06 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
JP7604020B2 (ja) 2015-05-29 2024-12-23 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料
JP2025032183A (ja) * 2015-05-29 2025-03-11 株式会社 イギス 環状ペプチド並びに該環状ペプチドを含む医薬品、外用剤および化粧料

Also Published As

Publication number Publication date
JP2010047614A (ja) 2010-03-04
EP1530588A2 (en) 2005-05-18
CA2488348A1 (en) 2004-02-05
WO2004011498A3 (en) 2004-06-24
WO2004011498A2 (en) 2004-02-05
AU2003246500A1 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
JP2010047614A (ja) 長時間持続性ナトリウム排泄増加性ペプチド誘導体
US20080199532A1 (en) Long Lasting Natriuretic Peptide Derivatives
JP4280070B2 (ja) 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
US7268113B2 (en) Long lasting growth hormone releasing factor derivatives
JP4115671B2 (ja) 長期間持続するインシュリン向性ペプチド
US7906482B2 (en) Anti-obesity agents
AU2002233089A1 (en) Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
AU2002233082A1 (en) Long lasting growth hormone releasing factor derivatives
CN101389648B (zh) 肽胃泌酸调节素衍生物
ZA200106676B (en) Long lasting insulinotropic peptides.
HK1123312A (en) Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
AU2005218012A1 (en) Long lasting growth hormone releasing factor derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060719

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090929

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100416